Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
State Street SPDR S&P Biotech ETF
(NY:
XBI
)
128.96
+0.41 (+0.32%)
Official Closing Price
Updated: 8:00 PM EDT, Apr 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about State Street SPDR S&P Biotech ETF
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Healthcare Stocks Are Looking Better But What About Biotech?
↗
February 20, 2024
Large cap biopharmacuiticals remain a core holding for growth and value despite political cross-currents on drug pricing.
Via
Talk Markets
Favoring IWM, XBI, And KRE
↗
February 18, 2024
It's time to employ ratios. Just like I utilize sector ratios such as XLF to XLU, XLY to XLP, or SPY to TLT, this is the time to look at IWM in comparison to the SPY.
Via
Talk Markets
Sunday ETF Review, Feb. 4, 2024
↗
February 04, 2024
Examining my
Via
Talk Markets
Topics
ETFs
Biotech And Medtech Portfolio Notes On A Fed Day
↗
January 31, 2024
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%
Via
Talk Markets
Topics
Economy
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
↗
January 26, 2024
There are several potential biotech breakthroughs likely to occur in 2024, and these three biotech stocks could see substantial gains
Via
InvestorPlace
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
↗
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
Biotech Playbook: Small Caps Show Momentum Peaking During
↗
January 15, 2024
The momentum of selected stocks was strong up until early January was encouraging but we need less volatility in period ahead to conform a new bull market.
Via
Talk Markets
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
↗
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
↗
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
2023 in Review: Key Stock Trends and Sector Shifts Unveiled
↗
January 05, 2024
Investors would be smart to pay attention to these stock trends, many of which are taking hold as the New Year begins.
Via
InvestorPlace
Satori Fund's Dan Niles Names Amazon, Meta Top Stocks To Own In 2024
↗
January 03, 2024
Satori Fund founder and portfolio manager Dan Niles is out with his top stock picks for 2024 and two Magnificent 7 names are at the top of the list.
Via
Benzinga
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
↗
January 03, 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.
Via
The Motley Fool
3 Thematic Growth ETFs to Load Up on Right Now
↗
December 30, 2023
These three thematic ETFs could be potent growth vehicles in years to come.
Via
The Motley Fool
Topics
ETFs
Small Caps Are On A Tear Including Speculative Biotechs
↗
December 26, 2023
So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation.
Via
Talk Markets
US Stocks Eye 7-Day Winning Streak As Mortgage Rates Fall Below 7%, Yields Tumble: What's Driving Markets Thursday?
↗
December 14, 2023
It’s shaping up to be a positive Thursday on Wall Street, with risk sentiment remaining robust after the Federal Reserve effectively opened the door to rate cuts in 2024.
Via
Benzinga
Topics
Economy
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday?
↗
December 13, 2023
Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates.
Via
Benzinga
Topics
Economy
Are These Biotechs Ready To Launch?
↗
December 09, 2023
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and...
Via
Talk Markets
Can Small Cap Biotech Stocks Continue To Run? Let’s Take A Look
↗
December 05, 2023
Over the past 4 weeks, we have seen a nice run in small-cap, speculative biotech stocks. This coincided with the pause in interest rates and expectations of the seasonal year-end rally.
Via
Talk Markets
Fed Rate Cut Speculations Rattle Stocks, Commodities Slide, Bitcoin Shines: What's Driving Markets Monday?
↗
December 04, 2023
Stocks opened the first week of December with significant losses, driven by some emerging concerns of exaggerated rate cut speculations within the trading community.
Via
Benzinga
Topics
Economy
Stocks, Gold, Bonds Rally Further, Dollars Tumbles As Traders Anticipate Fed Cuts: What's Driving Markets Friday?
↗
December 01, 2023
Kicking off the new month, Wall Street continued its strong November momentum, with major U.S. stocks rallying on Friday.
Via
Benzinga
Topics
Economy
S&P 500, Nasdaq Slip As Tech Underperforms, Oil Reacts to OPEC+: What's Driving Markets Thursday?
↗
November 30, 2023
Thursday’s trading session on Wall Street presents a mixed picture, characterized by notable fluctuations in major indices. While tech-heavy benchmarks like the S&P 500 and the Nasdaq 100 are...
Via
Benzinga
Topics
Stocks
Stocks Drift Higher On Stronger GDP Data, Oil Rebounds As OPEC+ Mulls Cuts: What's Driving Markets Wednesday?
↗
November 29, 2023
Stocks are experiencing their 16th green session out of the 20 so far in November, with the S&P 500 index reaching its highest level since early August, and the Nasdaq 100 just 4.4% below its all-time...
Via
Benzinga
US Stocks Rebound As Treasury Yields, Dollar Fall On Dovish Fed Remarks, Gold Hits $2,040: What's Driving Markets Tuesday?
↗
November 28, 2023
U.S. stocks experienced a welcome resurgence on Tuesday, buoyed by the latest comments from Federal Reserve officials.
Via
Benzinga
Topics
Economy
Biotech And Healthcare Portfolio Playbook For December 2023/24
↗
November 27, 2023
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.
Via
Talk Markets
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
↗
November 20, 2023
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.
Via
Talk Markets
Topics
ETFs
3 Biotech Stocks That Could Boom or Bust by 2025
↗
November 16, 2023
Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.
Via
InvestorPlace
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
↗
November 01, 2023
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic.
Via
Talk Markets
This Week’s Data Dump May Lead To More Stock Market Pain
↗
October 29, 2023
This week will feature data that is not only going to move the markets, but also set the tone for fourth-quarter GDP growth. This means the dollar and rates will be more volatile, and the equity market...
Via
Talk Markets
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
↗
October 24, 2023
The market's dour reaction to Roivant Sciences' latest deal doesn't add up.
Via
The Motley Fool
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
↗
October 23, 2023
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at...
Via
Talk Markets
Topics
Economy
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.